Search results
The main aim of the PlasTHER COST Action is to exploit the unprecedented possibilities of atmospheric pressure plasmas in medicine to share, develop and consolidate suitable therapies currently under investigation to make Europe’s science and healthcare world leaders in this field.
- 3rd Annual Meeting & Management Committee of COST Action ... - PlasTher
The main aim of the PlasTHER COST Action is to exploit the...
- 3rd Annual Meeting & Management Committee of COST Action ... - PlasTher
In these circumstances, this PlasTHER COST Action aims at establishing a synergistic network that articulates researchers, the medical community, industry or patient associations, among others, and coordinate the European activity in this domain to foster the leadership of Europe in this emerging field.
The main aim of the PlasTHER COST Action is to exploit the unprecedented possibilities of atmospheric pressure plasmas in medicine to share, develop and consolidate suitable therapies currently under investigation to make Europe’s science and healthcare world leaders in this field.
PlasTHER is a COST-Action Dealing with Therapeutical Applications of Cold Plasmas , with the participation of 24 countries and over 100 members. Despite scientific and technological progress in the medical field, many challenges still remain concerning the fight against cancer, tissue regeneration and repair or drug-resistant
COST Action CA20114 has the main aim and objective to exploit the possibilities of atmospheric pressure plasmas in medicine to share, develop and consolidate suitable therapies.
The Action will be carried out in accordance with the set of COST Implementation Rules approved by the Committee of Senior Officials (CSO), or any document amending or replacing them. The main aim and objective of the Action is to exploit the possibilities of atmospheric pressure plasmas in
Therapeutical applications of Cold Plasma (PlasTHER) is a COST Action project that sets a collaborative network of specialists designed to coordinate European activity in the plasma medicine field, and promotes the development of a coherent European research programme.
